Eli Lilly says retatrutide shows more weight loss compared to Ozempic
Eli Lilly's experimental drug retatrutide showed greater reduction in A1C and double the average weight loss in a head-to-head clinical study against Ozempic.
Eli Lilly's experimental drug retatrutide showed greater reduction in A1C and double the average weight loss in a head-to-head clinical study against Ozempic.
What's Your Reaction?
